Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: gerard mangiardi who wrote (404)	11/17/1998 9:41:00 AM
From: Troll	Respond to of 90042

DEPO gap up on strong value. FDA approval.

To: gerard mangiardi who wrote (404)	11/17/1998 12:29:00 PM
From: BulbaMan	Read Replies (1) \| Respond to of 90042

KIDE doesn't reveal this info. But in their 10K they say the following: "The typical licensing arrangement provides for the payment of royalties based upon a percentage of the manufacturer's aggregate net sales, at wholesale, of the products in question. LCI usually retains between 15% and 50% of the owner's licensing royalties, which generally range from 4% to 12% of net wholesale sales." LCI is KIDE's licensing subsidiary. And my guess is, given Pokemon's popularity, the percentages will be at the higher end of the ranges. So, for example, if Pokemon products do $1 billion at wholesale in 1999 (they sold $4 billion at retail in Japan in about 18 months), with Nintendo royalties at 9% and KIDE royalties at 35%, KIDE royalty revenues would be about $31.5 million.